Cogstate (CGS)

Shares / Stock Code

CGS

Stock Exchange / Sharemarket

Australian Securities Exchange

Cogstate (CGS) specialises in the development and commercialisation of rapid, computerised tests for the measurement of cognition (brain function). CGS is basically a biotechnology company established in 1999 with its headquarters situated in Melbourne and it was listed on ASX on 13 February, 2004. CogState's products address a variety of markets, the primary market being cognitive testing in clinical trials, where the technologies are used to quantify the effect of disease and of drugs, devices or other interventions on human subjects participating in clinical trials conducted by pharmaceutical, biotechnology, nutraceutical and functional food companies. Other markets include concussion management for elite and amateur athletes, memory monitoring and alertness testing for the workplace. CogState began selling tests of cognition into the clinical trials market in 2004 and since that time CogState has secured agreements with international organisations, including Pfizer, the Centers for Disease Control (USA), ALZA Corporation (a member of the Johnson and Johnson group) and Organon USA.

The Company is engaged in the sale of computerized tests of cognition and associated services including scientific consultancy, project management, data management, statistical analysis and reporting. CogState Limited is focused on the development and commercialization of computerized tests of cognition. The Company provides products and services to four markets: CogState Clinical Trials, CogState Sport, CogState Research and CogState WorkPlace.

The company also has ongoing therapeutic development projects for the treatment of Alzheimer’s Disease and Parkinson’s Disease, both of which involve small molecule drugs licensed to CGS and the major customers of the company include the government, general public, GPs and other health professionals. Major competitors are other companies involved in the treatment of neurologic disorders.